RAPP Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. (RAPP) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $17.2M.
Where they traded
Last open-market purchase: September 12, 2025 — 1.0 years ago, by PAUL STEVEN M .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Ceesay Abraham 2 fills | Chief Executive Officer | Sell 10b5-1 | 8,210 | $45.61 | $374.5K | 460,046 −1.8% of holding | |
| Yeleswaram Krishnaswamy 2 fills | Chief Development Officer | Sell 10b5-1 | 37,000 | $50.64 | $1.9M | 212,063 −14.9% of holding | |
| Ceesay Abraham | Chief Executive Officer | Sell 10b5-1 | 18,921 | $49.57 | $938.0K | 467,187 −3.9% of holding | |
| Yeleswaram Krishnaswamy | Chief Development Officer | Sell 10b5-1 | 13,160 | $50.00 | $658.0K | 232,862 −5.3% of holding | |
| Yeleswaram Krishnaswamy | Chief Development Officer | Sell 10b5-1 | 404 | $49.90 | $20.2K | 246,022 −0.2% of holding | |
| Ceesay Abraham 3 fills | Chief Executive Officer | Sell 10b5-1 | 28,958 | $48.01 | $1.4M | 511,402 −5.4% of holding | |
| Ceesay Abraham 2 fills | Chief Executive Officer | Sell 10b5-1 | 22,541 | $46.26 | $1.0M | 523,436 −4.1% of holding | |
| Ceesay Abraham 2 fills | Chief Executive Officer | Sell 10b5-1 | 2,210 | $42.11 | $93.1K | 537,614 −0.4% of holding | |
| Ceesay Abraham 2 fills | Chief Executive Officer | Sell 10b5-1 | 8,210 | $40.00 | $328.4K | 542,546 −1.5% of holding | |
| Gault Cheryl 4 fills | Chief Operating Officer | Sell 10b5-1 | 10,000 | $41.58 | $415.8K | 158,014 −6% of holding | |
| Ceesay Abraham 2 fills | Chief Executive Officer | Sell 10b5-1 | 8,220 | $39.83 | $327.4K | 548,903 −1.5% of holding | |
| Sell 10b5-1 | 18,572 | $40.05 | $743.8K | 6,280,525 −0.3% of holding | |||
| Sell 10b5-1 | 133,618 | $40.24 | $5.4M | 6,299,097 −2.1% of holding | |||
| Sell 10b5-1 | 5,018 | $40.31 | $202.3K | 6,432,715 −0.1% of holding | |||
| Sell 10b5-1 | 271,495 | $40.12 | $10.9M | 6,437,733 −4% of holding | |||
| Sell 10b5-1 | 426,005 | $40.32 | $17.2M | 6,709,228 −6% of holding | |||
| Yeleswaram Krishnaswamy | Chief Development Officer | Sell 10b5-1 | 20,225 | $39.99 | $808.8K | 246,426 −7.6% of holding | |
| Yeleswaram Krishnaswamy | Chief Development Officer | Sell 10b5-1 | 10,200 | $35.08 | $357.8K | 266,651 −3.7% of holding | |
| Yeleswaram Krishnaswamy | Chief Development Officer | Sell 10b5-1 | 9,165 | $34.97 | $320.5K | 276,851 −3.2% of holding | |
| Yeleswaram Krishnaswamy | Chief Development Officer | Sell 10b5-1 | 500 | $34.98 | $17.5K | 286,016 −0.2% of holding | |
| Yeleswaram Krishnaswamy | Chief Development Officer | Sell 10b5-1 | 360 | $34.90 | $12.6K | 286,516 −0.1% of holding | |
| Gault Cheryl 2 fills | Chief Operating Officer | Sell 10b5-1 | 10,000 | $28.19 | $281.9K | 162,753 −5.8% of holding | |
| Yeleswaram Krishnaswamy | Chief Development Officer | Sell 10b5-1 | 10,115 | $29.99 | $303.4K | 286,876 −3.4% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.